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Background: Smoking during pregnancy is harmful to the unborn child. Few smoking cessation interventions have
been successfully incorporated into standard antenatal care. The main aim of this study is to determine the
feasibility of a personal financial incentive scheme for encouraging smoking cessation among pregnant women.
Design: A pilot randomised control trial will be conducted to assess the feasibility and potential effectiveness of
two varying financial incentives that increase incrementally in magnitude ($20 vs. $40AUD), compared to no
incentive in reducing smoking in pregnant women attending an Australian public hospital antenatal clinic.
Method: Ninety (90) pregnant women who self-report smoking in the last 7 days and whose smoking status is
biochemically verified, will be block randomised into one of three groups: a. No incentive control group (n=30), b.
$20 incremental incentive group (n=30), and c. $40 incremental incentive group (n=30). Smoking status will be
assessed via a self-report computer based survey in nine study sessions with saliva cotinine analysis used as
biochemical validation. Women in the two incentive groups will be eligible to receive a cash reward at each of
eight measurement points during pregnancy if 7-day smoking cessation is achieved. Cash rewards will increase
incrementally for each period of smoking abstinence.
Discussion: Identifying strategies that are effective in reducing the number of women smoking during pregnancy
and are easily adopted into standard antenatal practice is of utmost importance. A personal financial incentive
scheme is a potential antenatal smoking cessation strategy that warrants further investigation.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) number: ACTRN12612000399897
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Smoking during pregnancy is a major public health issue
Smoking rates during pregnancy vary considerably,
within and between countries [1-4]. For example, recent
data illustrates large variations in smoking rates at the
end of pregnancy across England, ranging from 3% to
30% [4]. Similarly, the European perinatal health report* Correspondence: marita.lynagh@newcastle.edu.au
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reproduction in any medium, provided the orhave detailed smoking rates during the second trimester
from 5% in Lithuania to 22% in France [2]. In 2009, ap-
proximately 15% of Australian women smoked during
their pregnancy [3]. Rates are known to be higher in cer-
tain subpopulations such as lower socioeconomic, indi-
genous and ethnic minority groups [1,5]. Smoking
during pregnancy is directly associated with a number of
serious, harmful effects to the baby, including preterm
delivery, low birth weight and perinatal mortality [6,7].
Babies born to mothers who smoke during their preg-
nancy are also more likely to require special care or neo-
natal intensive care compared to mothers who do not
smoke [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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often not adopted into standard care
Despite a recent Cochrane review [8] reporting an abso-
lute difference of 6% reduction in smoking in late preg-
nancy following cessation interventions, very few are
adopted into standard care. Furthermore, pregnant
women who do continue to smoke may not receive sup-
port to quit [9]. For example, one Australian study found
that almost three-quarters of pregnant smokers in one
hospital did not receive smoking cessation advice at 30
weeks gestation [9]. Time restraints, competing pres-
sures, staff attitudes, lack of training or skill, administra-
tive barriers and lack of acceptable interventions for
women and staff were identified as some of the barriers
affecting implementation of smoking cessation into
standard antenatal care [5].Difficulties in accurately verifying women’ smoking status
Due to social stigma and social desirability, women often
underreport their current smoking behaviour, making it
difficult for clinic staff to accurately verify women’s
smoking status [1]. For example a recent study indicated
underestimations of self-reported smoking status during
pregnancy by as much as 25% [10]. The incorporation of
simple, rapid, biochemical validation methods of patients’
smoking status, may help to overcome this problem.
For instance, a study of family practice patients illu-
strated validity in using a semi-quantitative dipstick assay
(NicAlertW) to rapidly asses participant smoking status
through saliva cotinine analysis [11]. This study illu-
strated high sensitivity (99%) and high specificity (96%)
of the simple, 20-minute analysis of saliva cotinine [11].Contingent reinforcement is an appropriate strategy for
health behaviour change
The use of a contingent reinforcement schedule, such as
a Personal Financial Incentive (PFI), whereby individuals
are provided a monetary reward for their engagement in
a particular behaviour, may be an effective strategy to as-
sist in reducing smoking behaviour. Contingent
reinforcement has strong theoretical grounding within
behavioural psychology and more specifically the theory
of operant conditioning [12]. The lack of relevant health
promotion theories being applied to current smoking
cessation interventions for pregnant women has been
identified as a general criticism of interventions con-
ducted in this area [5]. Contingency management is
based on the notion that because behaviour is reinforced
by its consequences it can be modified by changing the
consequences [12]. There are several guiding principles
of contingency management suggested as potentially
relevant in treating substance use [13,14] and additionalprinciples which have been identified as effective to PFI
by previous literature reviews [15,16]. These include the
use of: behavioural contracting; positive reinforcements;
frequent and immediate feedback and rewards; and
incentives of sufficient and incremental magnitude [14].
The use of financial incentives also has a strong theoret-
ical and empirical grounding in economics, where the
monetary transfer influences the ratio of benefits to
costs, that in turn influences choice and decision
making.
Contingency management approaches have been
successfully applied to other health behaviours and sev-
eral have been effectively translated into real world prac-
tice [17]. For example, rewards or reduced premiums
have long been utilised by health insurers in the United
Kingdom and South Africa to encourage individuals to
engage in health promoting behaviours, such as exercise
or screening programs [16]. In Australia the Govern-
ment has successfully incorporated incentive-based pro-
grams to influence several health behaviours including,
immunisation and population growth [18-20]. These
programs resulted in an increase in child immunisation
rates from 56% in 1996 to 90% in 2003 [20]; and a sig-
nificant rise in fertility rates [18,19]. Additionally, the
results from one state-based study found no significant
differences in fertility rates of socially disadvantaged
groups compared to non-disadvantaged groups [19]. The
success of such financially based incentives introduced
by the government to influence health behaviours pro-
vides a strong platform for how a similar program to re-
duce smoking in pregnant women could be introduced
into practice, if found feasible and effective.
Contingent reinforcement has been found to be effective
in facilitating smoking cessation
A recent Cochrane review assessing smoking cessation
interventions in pregnant women found that interven-
tions that included an incentive component resulted in a
significantly larger effect in point-prevalence abstinence
during late-pregnancy, compared to other intervention
strategies [15]. Though PFI seems to be a potentially ef-
fective method in promoting smoking cessation in preg-
nant women, very few studies have assessed their
effectiveness among pregnant smokers in an Australian
antenatal care setting. Additionally, there have been no
Australian studies which have assessed the effect of re-
ward size on smoking cessation behaviour. One recent
descriptive study found pregnant women had mixed and
often unfavourable views regarding the acceptability and
potential effectiveness of using PFIs to assist women to
quit smoking [21]. However, a significantly higher per-
centage of smokers reported favourable views on the use
of PFI for smoking cessation, highlighting the ambiguity
surrounding the acceptability and potential benefit of
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research is conducted which aims to assess whether
a PFI smoking cessation program is feasible in an
Australian antenatal care setting.
Aims
The primary aim of this study is to test the feasibility of
a personal financial incentive (PFI)-based intervention at
encouraging smoking cessation in pregnant women
attending an Australian public hospital for antenatal
care. Specifically, the study will assess: (i) consent rates
of women to participate in the trial; (ii) loss to follow-up
rates of study participants; (iii) compliance with saliva
cotinine and hair cotinine analyses for biochemical valid-
ation (iv) acceptability of using a touchscreen computer
for self-reported smoking status and demographics; (v)
acceptability of saliva cotinine and hair cotinine analyses
for biochemical validation of smoking status; (vi) accept-
ability of incentives of varying magnitude ($20 vs. $40)
to staff and study participants; and (vii) the perceived
barriers and facilitators to using financial incentives in a
public antenatal clinic among clinic staff. Additionally,
secondary aims include: (i) to assess the potential effect-
iveness of the varying PFI amounts ($20 vs. $40) in redu-
cing smoking among study participants; (ii) to assess the
accuracy of self-report smoking status with saliva and
hair cotinine analysis; and (iii) to undertake a cost-
effectiveness analysis comparing the changes in costs of
the intervention and changes in quit rates between each
arm of the trial.
Methods/design
Study design
This is a proof-of-concept trial that will employ a rando-
mised control trial design to assess the potential efficacy
of personal financial incentives on pregnant women
smoking cessation rates; combined with a qualitative
analysis to investigate the acceptability of the interven-
tion to participants and clinic staff. The study will in-
volve a baseline survey; eight intervention sessions; and
a post-intervention telephone interview of participating
women and semi-structured interviews with clinic staff.
Self-reported smoking status will be validated through
saliva cotinine analysis using NicAlertW semi-quantita-
tive dipstick assay. Continuous or long-term smoking
cessation will be additionally assessed through hair ana-
lysis of patient’s cotinine levels using gas chromatog-
raphy – mass spectrometry.
Setting
The study will take place at the antenatal clinic within
#a large public teaching hospital in New South Wales,
Australia. The antenatal clinic operates a 5 days-a-week
service with most women presenting for an average of 6to 8 clinic visits over the course of their pregnancy. The
hospital manages approximately 4,300 deliveries each
year with the majority of these women receiving ante-
natal care predominantly through the hospital antenatal
clinic.
Participants
A sample of ninety (90) consenting pregnant women will
be recruited to participate. Women will be considered
eligible if they are: (1) aged at least 16 years; (2) present-
ing for their first antenatal visit; (3) less than 31 weeks
gestation; (4) sufficient in English language to complete
the survey; and (5) a current smoker (defined as having
smoked in last 7 days and a return a positive saliva sam-
ple for cotinine). Pregnant women will be ineligible to
participate if they have elected to receive shared ante-
natal care with their GP and/or are considered by clinic
staff to have a severe cognitive or psychiatric disorder;
currently being treated for chemical dependency other
than alcohol or tobacco; or have quit smoking before
their first antenatal appointment.
Randomization
Consenting women will be randomly allocated using
block randomisation into one of three groups: control
vs. smaller incentive ($AUS20) vs. larger incentive
($AUS40). The unit of randomisation will be the day
and session time (i.e. morning or afternoon) of the
patient’s first antenatal visit to minimise potential con-
tamination and deception. Randomisation will be per-
formed offsite, by an independent statistician prior to
study initiation. Allocation of days of the week to groups
will be done using Proc Plan in SAS.
Intervention
Two intervention arms will be assessed: (1) a $AUD20
incremental personal financial incentive; and (2) a
$AUD40 incremental personal financial incentive.
Women from both intervention groups will have an op-
portunity to receive a PFI at eight study intervention
sessions contingent upon smoking abstinence. The
amount of the monetary reward will begin at the base
amount (either $AUD20 of $AUD40) and will increase
by the base amount (either $AUD20 of $AUD40) at each
follow-up that participants are found to abstain from
smoking. Smoking abstinence will be assessed through
self-report and confirmed by saliva cotinine analysis.
Participants in the $AUD20 intervention group, who
quit smoking and maintain cessation for the entire eight
intervention sessions, will be potentially eligible to re-
ceive a total of $AUD720. Participants in the $AUD40
group will be potentially eligible to receive a total of
$AUD1440 if they maintain smoking abstinence for the
8 intervention sessions. If a participant fails to abstain at
Lynagh et al. BMC Public Health 2012, 12:1032 Page 4 of 8
http://www.biomedcentral.com/1471-2458/12/1032one intervention session or does not present for a sched-
uled visit they will not receive the incentive for that
period. However, the reward amount these women will
be eligible for during their next intervention session will
be the amount they missed during their previous session.
Their potential reward amount will remain at this
amount until they have successfully stopped smoking.
Procedures
All women who visit the hospital antennal clinic will
undergo their usual antenatal interview by the clinic
nurse. During this interview patients are asked about
their smoking status and basic demographic characteris-
tics. At this time potentially eligible patients will be
identified and informed that the study is being con-
ducted within the clinic. If women are interested they
will be directed to a Research Assistant (RA) who will be
stationed within the clinic. The RA will provide inter-
ested women with information describing the study. If
patients would like to take part in the study the RA will
obtain their written informed consent. Women will then
be asked to provide a saliva sample to confirm their
smoking status and complete a 15-minute baseline
Touchscreen computer survey, which will also ask for
their on-screen consent.
If a woman’s initial antenatal appointment has been
randomised to one of the two intervention groups, the
RA will verbally explain the details of their incentive
scheme, including, the schedule for monitoring, contin-
gencies being offered and the rules of payment. All parti-
cipants will be provided with a study package to take
home with them, which will contain information about
the study, referrals to Quit smoking self-help documents
and a Quit telephone help number (provided by clinic
midwives) and a letter of support to pass onto their part-
ner. Consenting women will be asked to attend 8 inter-
vention sessions, at which participants in the two
intervention groups will be eligible to receive a reward.
The 8 intervention sessions will occur approximately
fortnightly, during participants’ scheduled antenatal
appointments.
During each of the 8 intervention sessions, all women
will be asked to indicate their current smoking status
and whether they have quit smoking in the last 7 days.
Women will also be asked to provide a saliva sample
which will be analysed to confirm their self-report smok-
ing abstinence. Those women in the intervention groups
who self-report non-smoking and return a negative coti-
nine reading (level 0) will be provided with their monet-
ary incentive. A similar follow-up procedure will occur
seven more times (i.e. a total of 8 intervention sessions)
during women’s scheduled antenatal appointment.
During their eighth or final intervention session (i.e.
the last follow-up where women are eligible for areward) women will be asked to provide a hair sample to
allow for cotinine analysis using gas chromatography –
mass spectrometry. The hair analysis will allow for long-
term assessment of women’s smoking status. Women
will also be asked to consent to a post-intervention study
approximately six weeks after delivery. Women who
consent will be contacted via telephone. A short semi-
structured telephone interview will be conducted asses-
sing women’s acceptability of the intervention and their
current smoking status. A similar interview will be con-
ducted with clinic staff to assess their acceptability of,
and feedback on, the program. Both participants and
staff will be asked to provide feedback on whether they
believe the intervention was useful in increasing smok-
ing abstinence in pregnant women, whether the monet-
ary reward was sufficient and/or delivered in an
appropriate manner, whether they believe this interven-
tion could be easily introduced into standard care and
whether they experienced any problems with the inter-
vention.
Primary outcome measures
The RA will maintain detailed records documenting: (1)
the number of eligible women asked to take part in the
research study and how many of these women consent
to take part; (2) the number of participants who with-
draw from the study before study completion; and (3)
the number of women who complete or refuse to pro-
vide a saliva and/or hair sample for cotinine analysis.
This data will be used to measure the following three
primary outcomes: (i) consent rates; (ii) loss to follow-up
rates of study participants and (iii) participant compli-
ance with saliva and hair cotinine analyses for biochem-
ical validation of smoking status
Semi-structured interviews will be conducted with
both participants and clinic staff. Women will be asked a
serious of previously published and study specific ques-
tions about their experiences and perceptions of the
intervention trial. Specifically, six questions previously
published by Bryant et al. [22] will be included in the
interviews with study participants, to assess their accept-
ability of using a touchscreen computer for self-reported
smoking status and demographics. Five (5) items previ-
ously adapted by the researchers to assess pregnant
women’s acceptability of PFI as a strategy to decrease
smoking in pregnant women [21], will be included in
both participant and staff interviews. These questions
will be used to investigate the acceptability of incentives
of varying magnitude to staff and study participants.
Open-ended questions will also be included in both par-
ticipant and staff interviews to assess their thoughts on
the acceptability of using saliva and hair cotinine analysis
for biochemical validation of smoking status, as well as
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invectives.
Secondary outcome measures
To measure participants’ self-reported smoking status
women will complete one baseline and eight follow-up
self-report touchscreen computer surveys. The computer
survey was programed using Digivey survey software
[23]. Use of computer surveys to assess smoking status
has been shown to be a reliable and accurate method of
data collection [24], as well as being reported as enjoy-
able and easy to complete by most participants [22].
Questions assessing participants’ demographic character-
istics and factors previously found to be associated with
smoking status will also be included. The following
questions will be included in the self-report, touchscreen
computer surveys:
Baseline survey:
 Smoking status and history will be assessed through
standardised questions or questions adapted from
previous research [22,25-32] with many items based
on the previous the work of Bryant et al. [22,26,27]
Items will include: current smoking status [22,26],
number of cigarettes currently smoked per day [30],
smoking history, previous quit attempts, reductions
in smoking [25,26], strategies used to assist in
previous quit attempts [26,27], readiness/stages of
change [29,31], financial stress [33,34], whether they
smoked during any previous pregnancies [32]and
whether they attempted to quit or reduced smoking
during any previous pregnancies [26,32]. Questions
assessing women’s exposure to environmental smoke
will also be included [25,26,32].
 Demographic characteristics: women will be asked to
answer questions relating to their: age, date of birth,
highest level of education, Aboriginal or Torres
Strait Islander status, current household income,
marital status, number of previous pregnancies,
gestation period, postcode, number of adults and
children (<18 years) residing in their household.
 The Patient Health Questionnaire-2 (PHQ2) [35]:
Will be included as a short, simple measure of
participants’ levels of depression. The PHQ2 consists
of two questions, which assess respondent’s level of
depressed mood in the previous 2 weeks [35].
Respondents rate the frequency of depressed mood
and anhedonia on a four point likert scale, ranging
from 0 (“not at all”) to 3 (“nearly every day”) [35].
Total score on the PHQ2 range from 0 to 6. A score
of 4 has recommended as an appropriate cut-point
for screening for possible depressed mood in
pregnant women [36]. The PHQ-2 has evidence ofcriterion validity; as well as acceptable specificity
(92%) and sensitivity (83%) [35]. Previous research
has found a relationship between depression and
smoking status [37,38].
 Economic questions: Women will be asked to a
number of questions relating to their personal out-
of-pocket costs, time costs and health care
utilisation incurred as a result of the intervention.
 Social characteristics: women will be asked whether
their partner or others within their household
smoke.
Follow-up surveys: During each of the follow-up visits,
women will be asked to complete a brief touchscreen
computer survey using a number of items from the
baseline survey. Questions will assess their current
smoking status, number of cigarettes smoked per day
(if they have not abstained), changes in smoking
behaviour, partners’ current smoking status, exposure
to environmental smoke, the number of quit attempts
made, gestation age; the PHQ2 and efforts to engage
with quit smoking support services.
The following two biochemical analyses will be used to
validate women’s self-reported smoking status:
1. Saliva cotinine analysis: will be used to biochemically
validate self-reported smoking status for all
participants at baseline and each of the eight
intervention sessions using the NicAlertW
semiquantitative dipstick assay. A previous study
analysing 167 family practice patients using
NicAlertW illustrated acceptable levels of sensitivity
(99%) and specificity (96%) [11].Cotinine analysis
with the NicAlertW dipstick takes approximately 20
minutes and can be performed by untrained persons,
highlighting the potential utility of such a test in
clinical practice .
2.Hair cotinine analysis: will be undertaken during the
eighth or final intervention session. Participants will
be asked to provide a small sample of hair taken
from the nape of the neck. Samples will be
transported to an off-site laboratory for analysis. Hair
cotinine analysis can reliably quantify long-term
exposure to tobacco, with each centimetre of scalp
hair representing approximately 1 month of past
exposure [39]. Gas chromatography – mass
spectrometry will be used to analyse hair cotinine
levels, as it is considered the standard reference in
analysis of cotinine [40]. A cut-point of 0.2 ng/mg
has been found to distinguish between pregnant
active smokers and passive or unexposed with high
levels of sensitivity (91%), specificity (94%) and test
accuracy (91.7%) [40]. We will also validate hair
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comparing its accuracy against women’s self-report
smoking status and saliva cotinine throughout the
study.
Economic outcomes measures
The feasibility of undertaking a cost-effectiveness ana-
lysis will also be undertaken. This will include the collec-
tion of data on the costs of the interventions that would
include the amount of money received by each partici-
pant, and the costs of administering the payments in
terms of staff time and other resources used. The inter-
vention may also encourage patients to attend their
antenatal visits, and potentially other health care visits
associated with their pregnancy, more often than the
control group, and so data will also be collected on
patients’ utilisation of health services throughout the
study. The feasibility of obtaining these data from Medi-
care, PBS, and hospital separations data, including
obtaining patients’ consent, will be investigated and
compared to gathering this data directly from patients
using a standard questionnaire administered at each
visit. The costs incurred by patients are also likely to be
affected by the intervention. This will include savings in
purchasing cigarettes, and differences in out of pocket,
travel and time costs of attending if the intervention
influences health care utilisation. These data will be col-
lected from a short patient survey administered at each
visit. Out of pocket costs for GP visits and prescribed
medication can also be collected from MBS and PBS
records. The effectiveness data on quitting will be col-
lected as mentioned above, and combined with the data
on costs. Incremental cost-effectiveness ratios (ICERs)
will be calculated [41].Sample size
A convenience sample size totalling 90 women will be
recruited, with 30 women randomised to each of the
three study groups. As this is a proof-of-concept trial,
the sample size will not be adequately powered to
detected small differences however a sample size of 30
women in each group will allow for detection of a differ-
ence in smoking rates between groups of 24%, with 5%
significance level and 68% power. Based on previous
studies, this will be sufficient to provide an estimate of
the difference in proportions between groups for the fol-
lowing primary outcomes: (i) consent rates; (ii) lost to
follow-up rates; (iii) participant compliance to saliva and
hair cotinine analysis; (iv) acceptability of incentives and
validation measures, and the secondary outcome vari-
able, smoking cessation. To allow for a 20% drop-out
rate, a consent rate of 60% and 10% of women being in-
eligible, 208 pregnant women who smoke will beapproached. Based on a previous study conducted by the
investigators, approximately 17% of women seen at this
clinic are self-reported smokers [21].Analysis
Baseline demographic and social characteristics of
patients in all the three treatment groups will be sum-
marised separately. Continuous data will be expressed as
mean values with standard deviations (SD), and categor-
ical data will be presented as counts with percentages.Primary outcomes
Proportions and frequencies will be calculated to assess
the following outcomes: (i) participant consent rates; (ii)
loss to follow-up rates; and (iii) participant compliance
with saliva and hair cotinine analysis. Proportions and
frequencies will also be calculated for all closed-ended
questions included in the study participant and clinic
staff interviews to allow investigation of: (iv) participant
acceptability of touchscreen computers for self-reported
smoking rates and demographics; and (v) acceptability of
incentives to staff and study participants. Differences be-
tween experimental groups in the proportion of each of
these five primary outcomes and the secondary outcome
(proportion quit smoking) will be assessed through Fish-
er’s exact test. Differences between participant sub-
groups and these outcomes will also be assessed using
Fisher’s exact test. Although p-values from the above will
be reported, the focus will be on providing 95% confi-
dence intervals around point estimates for comparisons
of all three treatment arms.
Qualitative analysis will be performed on open-ended
questions included in participant and staff interviews in-
vestigating the following primary outcomes: (vi) accept-
ability of saliva and hair cotinine analyses for
biochemical validation of smoking status; and (vii) per-
ceived barriers and facilitators to using financial incen-
tives. All interviews will be transcribed verbatim and a
thematic analysis will be performed independently by
two of the research team members.Secondary outcomes
Quit rates
Although not adequately powered for detecting small
differences in the secondary outcomes, Fisher’s exact test
will be used to detect potential differences in smoking
cessation rates between groups and to demonstrate
potential effectiveness of the intervention. Differences
between experimental groups in the secondary outcome
- PHQ2 will be assessed using the Kruskal-Wallis test.
Fisher’s exact tests will be used to compare conditions
on post-partum smoking rates at 6 weeks after delivery.
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self-report smoking rates
Agreement between self-reported smoking status and
the cotinine saliva test strip will be assessed using the
Kappa statistic. Agreement between self reported smok-
ing status and hair cotinine results will also be assessed
using the Kappa statistic.
Economic analysis
Quantities of resources used (e.g. number of visits) will
be combined with their unit costs and calculated from
existing sources using standardised methods. Differences
in the average cost per patient in each arm of the trial
will be compared with differences in quitting rates.
These are used to calculate incremental cost-effective-
ness ratios (ICERs) for each intervention arm compared
to the control arm.
Ethics and safety approval
The study will be conducted in accordance with the
Helsinki Declaration and has received ethical approval
from both the Hunter New England Human Research
Ethics Committee (Ref No: 11/09/21/4.05) and the Uni-
versity of Newcastle Human Research Ethics Committee
(Ref No: H-2012-0047). Safety approval was also
obtained from the University of Newcastle Health and
Safety Review Committee (Ref: 26/2012).
Discussion
The harmful effects of smoking during pregnancy are
well known. Identifying strategies that are effective in re-
ducing the number of women smoking during preg-
nancy and that are easily adopted into standard
antenatal practice is of utmost importance. Despite nu-
merous intervention studies attempting to address this
issue very few have been successfully adopted into stand-
ard care. Given the past success of Personal-Financial
Incentives in changing people’s health behaviours and
being incorporating into routine care on a large scale, a
similar strategy to assist women in quitting smoking
seems to be a reasonable avenue for investigation. If the
use of PFI as a strategy to reduce smoking during preg-
nancy is viable and acceptable to women and clinic staff,
as well as illustrating promise of effectiveness, such a
strategy has the potential to fill the current void in
effective smoking cessation programs for pregnant
women.
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